Eraglusib combined with gemcitabine and nab-paclitaxel significantly improved overall survival in metastatic pancreatic ductal adenocarcinoma patients. The combination therapy showed a favorable ...

Add Yahoo as a preferred source to see more of our stories on Google. Cancer remains one of humanity's most formidable challenges, claiming the lives of millions every year despite decades of medical ...

Atebimetinib combined with modified chemotherapy achieved a 94% six-month overall survival rate in first-line pancreatic cancer patients, surpassing the typical 67% with standard treatment. The ...

Actuate Therapeutics has set its sights on getting elraglusib approved for pancreatic cancer after the glycogen synthase kinase‐3 beta (GSK-3β) drug showed a three-month survival increase in a phase 2 ...

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. Cystic adenocarcinoma (marked in red) of the pancreas (outlined in green). Contrast‑enhanced ...

High doses of vitamin C could be a new breakthrough in treating cancer. The University of Iowa Health Care Carver College of Medicine has shared results from a randomized, phase 2 trial testing the ...

Immuneering has reported 94% overall survival (OS) at six months in first-line pancreatic cancer, emboldening the biotech to start planning a pivotal trial to support accelerated approval of its MEK ...

They’re taking the plunge. A small number of Canadian cancer patients are testing a pill that contains healthy bacteria from human poop to see if it can extend their lives. “Pancreatic cancer has a ...

CHICAGO -- For the first time in a phase III trial, overall survival (OS) in unresectable pancreatic cancer improved significantly versus chemotherapy with the addition of tumor treating fields ...

Adding the investigational drug elraglusib to standard first-line gemcitabine and nab-paclitaxel (GnP) may extend the lives of some patients with metastatic pancreatic ductal adenocarcinoma (PDAC), ...

The MarketWatch News Department was not involved in the creation of this content. Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Dec. 12, 2025 /PRNewswire/ -- USANewsGroup.com News ...